Aventis

Bayer CEO considers merger only if stars are aligned

Thursday, May 5, 2011 12:40 PM

German-based Bayer is open to a “merger of equals” that would enhance its health-care unit without paying a premium for an acquisition, says Bayer’s chief executive officer Marijn Dekkers, according to a Bloomberg report.

More... »


Sanofi, Regeneron show positive results for Zaltrap

Wednesday, April 27, 2011 02:13 PM

Partners Sanofi-Aventis and Regeneron Pharmaceuticals report positive results for a late stage study evaluating Zaltrap (aflibercept), a colorectal cancer candidate.  

More... »


Sanofi-aventis collaborates with Stanford University

Monday, April 18, 2011 12:49 PM

Sanofi-aventis has entered into a research collaboration agreement that will last several years through the Stanford University Bio-X program, according to Fierce Biotech.  The Stanford program supports, organizes, and facilitates interdisciplinary, collaborative and innovative research projects in the early phases of development.

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »

Innovative paperless clinical trial study highlights time and cost savings

Friday, April 15, 2011 11:11 AM

Using interoperable digital identities, digital signatures and cloud computing can accelerate the initiation of a clinical trial and also lower costs, report a group of government and industry cancer researchers. They participated in the phase I of a pilot study that used interoperable digital identities and cloud-based digital signatures to eliminate reliance on paper forms in clinical trials.

More... »

Shanghai Pharmaceuticals inks $3 billion in overseas contracts

Thursday, April 14, 2011 01:07 PM

Shanghai Pharmaceuticals will ink more than $3.06 billion worth of procurement contracts with 69 worldwide pharmaceutical companies this year, according to Global Times.

More... »

Sanofi-Aventis seeks buyer for dermatology unit

Thursday, April 14, 2011 11:54 AM

French drugmaker, Sanofi-aventis, is seeking a buyer for its U.S. dermatology business that could amount to a $433 million sale, according a Bloomberg report.

More... »

Neuroscience drug development slows, requires funding

Tuesday, March 29, 2011 11:49 AM

Many European pharmaceutical companies have significantly reduced their workflow in the realm of neuroscience, according to Fierce Biotech. Companies are challenged with a high risk of trial failure while investors demand new products. 

More... »

Sanofi collaborates with Columbia University

Friday, March 25, 2011 11:28 AM

Sanofi-aventis has entered into a collaboration with Columbia University Medical Center to develop diabetes drugs, according to PharmaTimes.

More... »

Sanofi/Regeneron's aflibercept fails trial

Thursday, March 17, 2011 01:06 PM

Sanofi-aventis and partner Regeneron have suffered a setback with their investigational agent aflibercept failing a late-stage trial for non-small cell lung cancer (NSCLC), according to PharmaTimes.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs